Arcutis Biotherapeutics, Inc. (ARQT)
Nasdaq · Healthcare · Biotechnology
$25.15−0.04%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $3.2B
- P/E (trailing)
- 114.3
- Forward P/E
- 18.5
- 52-week range
- $19.30 – $31.77
- 52-week change
- +22.31%
- EPS (trailing)
- $0.22
- Next earnings
- Oct 27, 2026
Fiscal year to Dec 2025
- Revenue
- $376M (+91.35%)
- Net income
- −$16.1M
- Operating margin
- −3.3%
- Diluted EPS
- −$0.13
- Free cash flow
- −$6.3M
From the company’s annual report on SEC EDGAR.
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Headquarters: Westlake Village, United States · 354 employees · arcutis.com